Chiral Emcure

Pune, India Founded: 1981 • Age: 45 yrs Listed
Research and manufacturing of pharmaceutical APIs, formulations, and biotechnology products globally.
Request Access
Report Incorrect Data
Page last updated

About Chiral Emcure

Chiral Emcure is a publicly listed company based in Pune (India) founded in 1981. Research and manufacturing of pharmaceutical APIs, formulations, and biotechnology products globally. It operates on a B2B and Outsourcing model. The company has 6,877 employees. Its Indian entity Emcure Pharmaceuticals Limited reported revenue of ₹9,335 Cr. Chiral Emcure offers products and services including APIs, Formulations, and Biotechnology Products. Its focus areas include Pharmaceuticals, Biotechnology, Research and API Manufacturing. Similar companies include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals; 1 of its 3 listed similar companies has raised funding.

Company details

Emcure is a vertically integrated pharmaceutical company that conducts research and manufacturing of active pharmaceutical ingredients (APIs), formulations, and biotechnology products. It serves as a preferred outsourcing partner for major multinational corporations in India and international markets. Based in Pune, India, the company focuses on high-quality production and innovation, while adhering to industry standards and partnering with global entities for distribution and development.

  • Headquarters Pune, India
  • Employees 6,877
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website chiralemcure.com
  • Social Facebook
  • Legal Name Emcure Pharmaceuticals Limited
  • Date of Incorporation 16 Apr, 1981
  • Jurisdiction Pune, Maharashtra, India
Operational Areas
Healthcare → Clinical Trials & Research Tech
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹42,044 Cr

    EMCURE · NSE

  • Share Price
    ₹2,216.20

    -2.80% today

  • Revenue
    ₹9,204 Cr

    FY 2025-26 · +16.6% YoY

  • EBITDA
    ₹1,714 Cr

    Margin 18.6%

  • Net Profit
    ₹945 Cr

    FY 2025-26 · +48.3% YoY

  • P/E (TTM)
    37.7x

    P/B 7.9x

  • ROE
    20.0%

    ROCE 23.1%

  • Debt / Equity
    0.27

    Interest cover 11.1x

  • Employee Count
    6,877

Products & Services of Chiral Emcure

Chiral Emcure offers a comprehensive portfolio of products and services, including APIs, Formulations, and Biotechnology Products.

APIs
Manufacturing

Production of active pharmaceutical ingredients for drug development.

Formulations
Drug Development

Creation of finished pharmaceutical products for various applications.

Biotechnology Products
Biotech

Development of biotechnology-based pharmaceuticals and solutions.

Board of directors of Emcure Pharmaceuticals Limited (Chiral Emcure)

Emcure Pharmaceuticals Limited is the primary company behind Chiral Emcure. The board of Emcure Pharmaceuticals Limited currently have 10 directors; the longest-serving is Satish Ramanlal Mehta, appointed in 1981. 25 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Satish Ramanlal Mehta
DIN 00118691
Managing Director16 Apr 198145 yrs 6 moEmcure Pharmaceuticals Limited
Mukund Keshao Gurjar
DIN 00026843
Whole-time director23 Jul 200125 yrs 3 moEmcure Pharmaceuticals Limited
Sunil Rajanikant Mehta
DIN 00118469
Whole-time director05 Jun 201313 yrs 5 moEmcure Pharmaceuticals Limited
Namita Vikas Thapar
DIN 05318899
Whole-time director28 Jul 201412 yrs 3 moEmcure Pharmaceuticals Limited
Shailesh Kripalu Ayyangar
DIN 00268076
Director16 Apr 20215 yrs 6 moEmcure Pharmaceuticals Limited
Vijay Keshav Gokhale
DIN 09134089
Director16 Apr 20215 yrs 6 moEmcure Pharmaceuticals Limited
Vidya Rajiv Yeravdekar
DIN 02183179
Director16 Apr 20215 yrs 6 moEmcure Pharmaceuticals Limited
Samit Satish Mehta
DIN 00332562
Whole-time director28 Jul 20224 yrs 3 moEmcure Pharmaceuticals Limited
Chinnadharavaram Sundaresan Muralidharan
DIN 00014740
Director01 Apr 20267 moEmcure Pharmaceuticals Limited
Raman Pillai Raghu Kumar
DIN 01983106
Director06 Aug 20263 moEmcure Pharmaceuticals Limited

IPO & Listings of Chiral Emcure

Chiral Emcure is a publicly listed company on the NSE with ticker symbol EMCURE in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: EMCURE
  • Listed entityEmcure Pharmaceuticals Limited
  • Exchange sectorPharmaceuticals

Financials of Chiral Emcure

Exchange-reported figures of Emcure Pharmaceuticals Limited, the listed company behind Chiral Emcure (NSE: EMCURE).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹9,204 Cr
+16.6% YoY
EBITDA
₹1,714 Cr
+17.5% YoY
Profit After Tax
₹945 Cr
+48.3% YoY
Net Worth
₹4,950 Cr
+11.3% YoY
Total Assets
₹6,609 Cr
+9.8% YoY
Total Debt
₹1,521 Cr
+48.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue9,2047,8966,6585,9865,8555,0335,049
Revenue growth+16.6%+18.6%+11.2%+2.2%+16.3%-0.3%-
EBITDA1,7141,4581,2201,1751,3301,023600
EBITDA margin+18.6%+18.5%+18.3%+19.6%+22.7%+20.3%+11.9%
Profit before tax1,287971727747973652105
Net profit945638504537662421159
Net profit margin+10.3%+8.1%+7.6%+9.0%+11.3%+8.4%+3.2%
EPS (₹)48.7635.9627.5029.4236.6223.154.62
Balance sheet
Total assets6,6096,0205,8115,0894,4454,9664,686
Net worth4,9504,4462,9522,5011,9882,2731,912
Total debt1,5211,0232,3352,3342,2172,3102,327
Cash & bank148165232458313524164
Net working capital2,7072,3872,1022,2921,8481,9151,429
Cash flow
Cash from operations9448521,097747768704500
Cash from investing(1,175)(96.05)(715)(468)(574)(256)(168)
Cash from financing343(814)(164)(145)(152)(189)(301)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,8202,5802,4702,3632,2702,1012,1161,963
Revenue growth (YoY)+24.3%+22.9%+16.7%+20.4%+13.4%+15.7%--
Other income3.252.0714.291.853.123.704.453.90
EBITDA588532480455475413392355
EBITDA margin+20.8%+20.6%+19.4%+19.2%+20.9%+19.7%+18.5%+18.1%
Depreciation11011010610510599.4696.8496.81
Interest35.5831.5446.4037.9832.5426.7639.0331.78
Profit before tax446394341314341291261230
Tax12110197.4482.4290.0575.9763.3773.83
Net profit325292244231251215197156
EPS (₹)17.1415.5012.8412.1612.8510.929.978.12
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue5,2434,3823,4983,1073,3873,1542,376
Revenue growth+19.7%+25.3%+12.6%-8.3%+7.4%+32.8%-
EBITDA998623433432795725379
EBITDA margin+19.0%+14.2%+12.4%+13.9%+23.5%+23.0%+16.0%
Profit before tax944428200212616557225
Net profit752268162165447434208
Net profit margin+14.3%+6.1%+4.7%+5.3%+13.2%+13.8%+8.8%
EPS (₹)38.6616.748.888.8524.7123.259.69
Balance sheet
Total assets5,3723,9383,5933,6673,4264,0113,202
Net worth3,7113,0241,9351,8421,7132,3021,915
Total debt1,5978571,5951,7731,5791,6651,243
Cash & bank16.8813.8032.1214147.8826139.22
Net working capital1,5031,0089881,2201,2741,3921,170
Cash flow
Cash from operations424558585505428775385
Cash from investing(947)(438)(173)(271)(394)(836)(169)
Cash from financing526(49.25)(288)(54.52)(343)30.97(45.87)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,6681,4511,4681,4181,2611,0971,2781,029
Revenue growth (YoY)+32.3%+32.3%+14.8%+37.9%+14.1%+13.0%--
Other income33.5425.0334.5213822.7521.5222.4019.41
Total expenses1,2721,1111,0961,1471,0368721,034904
EBITDA396340372271225224245124
EBITDA margin+23.8%+23.4%+25.3%+19.1%+17.8%+20.5%+19.1%+12.1%
Depreciation65.0163.1763.0462.1461.7459.8256.9156.65
Interest32.4232.7836.8733.1527.7120.5424.0719.93
Profit before tax33226930631415816618667.24
Tax83.9568.5772.5755.5140.2742.8846.4917.05

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,8202,5802,4702,3632,2702,1012,1161,963
Revenue growth (YoY)+24.3%+22.9%+16.7%+20.4%+13.4%+15.7%--
Other income3.252.0714.291.853.123.704.453.90
EBITDA588532480455475413392355
EBITDA margin+20.8%+20.6%+19.4%+19.2%+20.9%+19.7%+18.5%+18.1%
Depreciation11011010610510599.4696.8496.81
Interest35.5831.5446.4037.9832.5426.7639.0331.78
Profit before tax446394341314341291261230
Tax12110197.4482.4290.0575.9763.3773.83
Net profit325292244231251215197156
EPS (₹)17.1415.5012.8412.1612.8510.929.978.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue9,2047,8966,6585,9865,8555,0335,049
Revenue growth+16.6%+18.6%+11.2%+2.2%+16.3%-0.3%-
Other income13172.7956.9945.9163.4733.8882.31
Total expenses7,4896,4385,4384,8114,5254,0104,448
Employee cost1,5521,4461,2921,1171,0129031,106
EBITDA1,7141,4581,2201,1751,3301,023600
EBITDA margin+18.6%+18.5%+18.3%+19.6%+22.7%+20.3%+11.9%
Depreciation415384312260245250321
Interest144176237214176155257
Profit before tax1,287971727747973652105
Tax3462642001852702334.73
Net profit945638504537662421159
Net profit margin+10.3%+8.1%+7.6%+9.0%+11.3%+8.4%+3.2%
EPS (₹)48.7635.9627.5029.4236.6223.154.62
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital190189181181181181181
Reserves & surplus4,7604,2572,7712,3201,8072,0921,731
Shareholders' funds (net worth)4,9504,4462,9522,5011,9882,2731,912
Minority interest26.6419516914912794.9972.41
Secured loans1,2047301,7231,8831,8001,9552,513
Unsecured loans317293612452418355(187)
Total debt1,5211,0232,3352,3342,2172,3102,327
Total liabilities6,6096,0205,8115,0894,4454,9664,686
Assets
Gross block5,9525,4385,0523,8023,4723,2493,523
Net block3,3193,1973,1252,1472,0442,1882,382
Capital work in progress273177159411320302485
Investments19.7095.3831825.0025.000.000.00
Inventories2,3981,9321,5251,3831,4491,5141,173
Sundry debtors2,5632,0021,8591,6481,3091,4751,145
Cash & bank balances148165232458313524164
Loans & advances504380344346353204221
Total current assets5,6124,4803,9603,8363,4243,7172,703
Total current liabilities2,9052,0931,8581,5441,5761,8021,274
Net working capital2,7072,3872,1022,2921,8481,9151,429
Total assets6,6096,0205,8115,0894,4454,9664,686
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(14.31)43.99(175)(308)(350)(609)(641)
Net cash from operating activities9448521,097747768704500
Net cash from investing activities(1,175)(96.05)(715)(468)(574)(256)(168)
Net cash from financing activities343(814)(164)(145)(152)(189)(301)
Net change in cash112(58.30)21913441.8725931.86
Closing cash148165232458313524164
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+16.6%+18.6%+11.2%+2.2%+16.3%-0.3%-
EBITDA growth+17.6%+19.6%+3.8%-11.7%+30.0%+70.4%-
PBT growth+32.5%+33.6%-2.7%-23.2%+49.2%+519.1%-68.1%
Net income growth+48.3%+26.6%-6.2%-19.0%+57.2%+165.2%-
Revenue CAGR (3Y)+15.4%+10.5%+9.8%+5.8%+7.5%--
EBITDA CAGR (3Y)+13.4%+3.1%+6.0%+25.1%+28.6%--
Profitability & leverage
Net income margin+10.2%+9.0%+7.9%+9.4%+12.0%+8.3%+2.0%
Return on capital employed+23.1%+20.0%+18.2%+20.8%+25.0%+21.1%+10.4%
Return on net worth+20.0%+19.1%+19.4%+25.0%+33.0%+20.1%+9.4%
Debt / equity0.270.450.861.011.061.111.19
Long-term debt / equity0.100.190.340.380.360.390.42
Interest cover11.0616.3626.1423.3516.2220.0491.77
Efficiency & per share
Fixed asset turnover1.621.511.501.651.741.491.52
Inventory turnover4.254.574.584.233.953.754.39
Debtors turnover4.034.093.804.054.213.844.77
EPS (₹)48.7635.9627.5029.4236.6223.154.62
Dividend per share (₹)3.603.002.002.003.001.002.50
Book value per share (₹)261.09234.65162.97138.30109.90125.68105.72
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,6681,4511,4681,4181,2611,0971,2781,029
Revenue growth (YoY)+32.3%+32.3%+14.8%+37.9%+14.1%+13.0%--
Other income33.5425.0334.5213822.7521.5222.4019.41
Total expenses1,2721,1111,0961,1471,0368721,034904
EBITDA396340372271225224245124
EBITDA margin+23.8%+23.4%+25.3%+19.1%+17.8%+20.5%+19.1%+12.1%
Depreciation65.0163.1763.0462.1461.7459.8256.9156.65
Interest32.4232.7836.8733.1527.7120.5424.0719.93
Profit before tax33226930631415816618667.24
Tax83.9568.5772.5755.5140.2742.8846.4917.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue5,2434,3823,4983,1073,3873,1542,376
Revenue growth+19.7%+25.3%+12.6%-8.3%+7.4%+32.8%-
Other income312142138125133112138
Total expenses4,2463,7593,0652,6752,5932,4291,996
Employee cost821782706649604551545
EBITDA998623433432795725379
EBITDA margin+19.0%+14.2%+12.4%+13.9%+23.5%+23.0%+16.0%
Depreciation247225205179166156155
Interest118113166167145123137
Profit before tax944428200212616557225
Tax21111139.0852.2717013749.47
Net profit752268162165447434208
Net profit margin+14.3%+6.1%+4.7%+5.3%+13.2%+13.8%+8.8%
EPS (₹)38.6616.748.888.8524.7123.259.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital190189181181181181181
Reserves & surplus3,5212,8351,7541,6611,5322,1211,734
Shareholders' funds (net worth)3,7113,0241,9351,8421,7132,3021,915
Secured loans8102511,4161,6691,5791,5971,191
Unsecured loans7876061801040.0067.1852.59
Total debt1,5978571,5951,7731,5791,6651,243
Total liabilities5,3723,9383,5933,6673,4264,0113,202
Assets
Gross block3,3233,1542,9532,4722,0312,0131,762
Net block1,7541,7591,7181,4331,1511,2781,166
Capital work in progress12299.11106253239192326
Investments1,424678684690563864408
Inventories1,2071,038770710730622444
Sundry debtors1,5351,1911,1031,0541,0099991,138
Cash & bank balances16.8813.8032.1214147.8826139.22
Loans & advances283218218234354334186
Total current assets3,0412,4602,1232,1402,1422,2151,808
Total current liabilities1,5381,4521,135919868824637
Net working capital1,5031,0089881,2201,2741,3921,170
Total assets5,3723,9383,5933,6673,4264,0113,202
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(17.53)(88.91)(213)(393)(84.29)(54.35)(225)
Net cash from operating activities424558585505428775385
Net cash from investing activities(947)(438)(173)(271)(394)(836)(169)
Net cash from financing activities526(49.25)(288)(54.52)(343)30.97(45.87)
Net change in cash2.5171.38124180(309)(29.94)170
Closing cash16.8813.8032.1214147.8826139.22
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.7%+25.3%+12.6%-8.3%+7.4%+32.8%-
EBITDA growth+60.1%+44.1%+0.1%-45.6%+9.6%+91.2%-
PBT growth+120.8%+114.0%-5.9%-65.6%+10.6%+148.1%-39.3%
Net income growth+180.4%+65.1%-1.5%-63.1%+3.0%+108.6%-
Revenue CAGR (3Y)+19.1%+9.0%+3.5%+9.4%+11.4%--
EBITDA CAGR (3Y)+32.1%-7.8%-15.8%+4.5%+14.1%--
Profitability & leverage
Net income margin+14.0%+7.2%+4.6%+5.2%+13.2%+13.3%+7.4%
Return on capital employed+22.8%+14.4%+10.1%+10.7%+20.5%+18.9%+13.1%
Return on net worth+21.8%+12.8%+8.5%+9.0%+22.3%+20.0%+11.3%
Debt / equity0.360.490.890.940.790.690.67
Long-term debt / equity0.220.240.340.340.290.280.26
Interest cover15.7528.3772.9365.7323.0821.6861.18
Efficiency & per share
Fixed asset turnover1.621.441.291.381.731.671.43
Inventory turnover4.674.854.734.315.015.925.06
Debtors turnover3.853.823.243.013.372.952.32
EPS (₹)38.6616.748.888.8524.7123.259.69
Dividend per share (₹)3.603.002.002.003.001.002.50
Book value per share (₹)195.72159.61106.82101.8494.69127.27105.86

Similar companies to Chiral Emcure

Chiral Emcure has 3 listed similar companies in our database, 1 of them funded. They include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Indoco Remedies
indoco.com1947Mumbai, India6,291
APIs manufacturing and formulation services are provided in therapeutic segments.
Concord Biotech
concordbiotech.com2000Ahmedabad, India1,598
APIs and enzymes are manufactured through fermentation by the CDMO.
BDR Pharmaceuticals Internationals
bdrpharma.com2003Mumbai, India$88.16M1,864
APIs and finished products are developed and manufactured.
Premium access

Detailed similar companies of Chiral Emcure

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Clinical Trials & Research Tech

2 companies that operate in the same segment as Chiral Emcure (Clinical Trials & Research Tech) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Veeda Clinical Research
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare.
2004Ahmedabad, Gujarat, IndiaUSD 50.52 M902
Zenotech Laboratories
Generic injectables for oncology and anesthesiology are manufactured.
1989Hyderabad, Telangana, IndiaUSD 4.22 M228
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Chiral Emcure

EMCURE: Q2 CONS NET PROFIT 3.3B RUPEES VS 2.44B (YOY)
Exchange Update • 7 days ago
EMCURE: Q2 REVENUE 28B RUPEES VS 22.7B (YOY)
Exchange Update • 7 days ago
EMCURE: Q2 EBITDA 5.87B RUPEES VS 4.7B (YOY); Q2 EBITDA MARGIN 20.84% VS 20.94% (YOY)
Exchange Update • 7 days ago
EMCURE: Rs. 28.98 Crores NSE Block Trade; for ~ 152,544 Shares, at Rs. 1900.10
Exchange Update • 1 month ago
Emcure Pharmaceuticals Ltd.: Rs. 17.47 Crores NSE Block Trade; for ~ 90,289 Shares, at Rs. 1934.50
Exchange Update • 1 month ago
Buzzing Stocks: Emcure Pharma gains 3% on USFDA EIR; PFC slips 3% after mixed Q1 earnings
Moneycontrol • 3 months ago
Emcure to double down on complex generics, biosimilars, ARVs, says COO Samit Mehta
Moneycontrol • 3 months ago
Emcure Pharma shares hits 52-week high post USFDA EIR for Gujarat facility
Moneycontrol • 3 months ago
Buy Emcure; target of Rs 2300: Motilal Oswal
Moneycontrol • 3 months ago
EMCURE: Q1 FY 2027 saw 22.8% revenue and 35.4% PAT growth, with margin expansion and strong global momentum
Quartr • 3 months ago
Premium access

Complete news archive for Chiral Emcure

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chiral Emcure

Chiral Emcure was founded in 1981.

Chiral Emcure is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.

Chiral Emcure has 6,877 employees.

The primary company behind Chiral Emcure, Emcure Pharmaceuticals Limited, reported revenue of ₹9,335 Cr for FY 2026, up 17% year on year.

Emcure is a vertically integrated pharmaceutical company that conducts research and manufacturing of active pharmaceutical ingredients (APIs), formulations, and biotechnology products. It serves as a preferred outsourcing partner for major multinational corporations in India and international markets. Based in Pune, India, the company focuses on high-quality production and innovation, while adhering to industry standards and partnering with global entities for distribution and development.

Chiral Emcure's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Indoco Remedies.

Chiral Emcure offers APIs, Formulations, and Biotechnology Products.

Yes, Chiral Emcure is publicly traded on NSE under the ticker symbol EMCURE.

Chiral Emcure operates through Emcure Pharmaceuticals Limited.

The legal entities of Chiral Emcure currently have 12 directors, including Shailesh Kripalu Ayyangar, Satish Ramanlal Mehta, Mukund Keshao Gurjar and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available